Corbus Pharmaceuticals Holdings Inc's Comment on Sales, Marketing and Customers
The company serves customers in the pharmaceutical industry, including government entities and other payers seeking reimbursement for its product candidates. Its markets include the U.S. healthcare system, with specific reference to Medicare Part D coverage, as well as foreign countries such as those in the European Union. The company faces pricing pressures from managed healthcare, managed care organizations, and legislative proposals. Third-party payers may require pre-approval for coverage of new or innovative therapies. Pricing and reimbursement regulations vary by country, with European Union member states able to restrict reimbursement and control prices. The company engages consultants, clinical research organizations, and third parties to support pre-clinical and clinical studies, manufacturing, and regulatory functions. Customers and markets identified in filings include Corbus Pharmaceuticals, Inc. and JB Therapeutics Inc.
News about Corbus Pharmaceuticals Holdings Inc Contracts
CRB-701 (SYS6002): Promising Results in Targeting Nectin-4 Positive TumorsCorbus Pharmaceuticals Holdings, Inc. has recently announced encouraging safety and efficacy results for their next-generation antibody drug conjugate, SYS6002 (CRB-701), in patients with Nectin-4 positive tumors. The clinical update of this ongoing trial was presented at the American Society of Clinical Oncology (ASCO) Annual Conference in 2024.Nectin-4 is a protein that is overexpressed in various types of cancer, including breast, lung, bladder, ovarian, and pancreatic cancers. Targeting Nectin-4 with antibody drug conjugates has shown promising results in preclinical studies, leading to the development of SYS6002 (CRB-701). This ne...
Corbus Pharmaceuticals Holdings, Inc. has recently announced encouraging safety and efficacy results from the first-in-human clinical study of their investigational drug, CRB-701 (SYS6002), presented at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). The ongoing Phase 1 dose escalation study is being conducted in China and focuses on patients with metastatic urothelial cancer (mUC) and other solid tumors with nectin-4 positive tumors.Promising Results Shared:The results presented at ASCO GU included data from the first eighteen participants enrolled in the study, representing the initial six dose cohorts ranging from 0.2 to 3.6mg/kg. The primary of the study is to e...
Corbus Pharmaceuticals Holdings, Inc., a progressive biopharmaceutical company, announced the release of the abstract for the first-in-human Phase 1 dose escalation study of SYS6002 (also known as CRB-701). The abstract will serve as the basis for the upcoming presentation, intended to launch at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). The symposium will take place from January 25 to 27, 2024, in San Francisco, California, as well as online. This crucial study s commencement marks a significant step towards enhancing the knowledge around SYS6002 (CRB-701). Initial indicators show the compound as a potential asset to serving the medical and pharmaceutical compa...
NORWOOD, Mass., Dec. 18, 2023 - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) has recently made a significant announcement that holds tremendous potential for advancing precision oncology. The company disclosed that the Phase 1 clinical data from a dose escalation study of CRB-701 (SYS6002), a next-generation antibody-drug conjugate (ADC), has been accepted for presentation at the esteemed 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). This symposium is scheduled to take place from January 25-27, 2024, in San Francisco, CA, as well as virtually. CRB-701 is an innovative ADC specially designed to target nectin-4, utilizing a third-generation, site-sp...
Corbus Pharmaceuticals Holdings Inc’s Comment on Sales, Marketing and Customers
The company serves customers in the pharmaceutical industry, including government entities and other payers seeking reimbursement for its product candidates. Its markets include the U.S. healthcare system, with specific reference to Medicare Part D coverage, as well as foreign countries such as those in the European Union. The company faces pricing pressures from managed healthcare, managed care organizations, and legislative proposals. Third-party payers may require pre-approval for coverage of new or innovative therapies. Pricing and reimbursement regulations vary by country, with European Union member states able to restrict reimbursement and control prices. The company engages consultants, clinical research organizations, and third parties to support pre-clinical and clinical studies, manufacturing, and regulatory functions. Customers and markets identified in filings include Corbus Pharmaceuticals, Inc. and JB Therapeutics Inc.
Sources:
Corbus Pharmaceuticals Holdings Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Corbus Pharmaceuticals Holdings Inc’s corporate clients.
For your research, we’ve provided 9 tables on Corbus Pharmaceuticals Holdings Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
